Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934240 | 0.93 | P2RY14 (0.65) | P2RY14ALOX5TSHRSMN1; SMN2LTB4R | |
| SCHEMBL2927190 | 0.92 | P2RY14 (0.64) | P2RY14ALOX5PTGER4LTB4RLTB4R2 | |
| SCHEMBL2935431 | 0.90 | P2RY14 (0.61) | P2RY14ALOX5PTGER4LTB4RLTB4R2 | |
| SCHEMBL2927585 | 0.88 | P2RY14 (0.59) | P2RY14ALOX5LTB4RLTB4R2 | |
| SCHEMBL2933902 | 0.88 | P2RY14 (0.59) | P2RY14ALOX5LTB4RLTB4R2MRGPRX4 | |
| SCHEMBL2929206 | 0.87 | P2RY14 (0.58) | P2RY14ALOX5 | |
| SCHEMBL2929207 | 0.86 | P2RY14 (0.57) | P2RY14ALOX5LTB4RLTB4R2MRGPRX4 | |
| SCHEMBL2933139 | 0.84 | P2RY14 (0.56) | P2RY14ALOX5LTB4RLTB4R2MRGPRX4 | |
| SCHEMBL13057709 | 0.83 | P2RY14 (0.53) | P2RY14LTB4RLTB4R2MRGPRX4SLC22A12 | |
| SCHEMBL2957088 | 0.82 | P2RY14 (0.53) | P2RY14ALOX5PTGER4TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD (CA) | 2010-11-25 | — | — | US | disclosed |
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD (CA) | 2010-11-25 | — | — | US | disclosed |
| EP-2229373-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | Merck Frosst Canada Ltd. (CA) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009070873-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD. (CA) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009070873-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | MERCK FROSST CANADA LTD. (CA) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298347-A1 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY | GPR119, GPR52, GPR35 | P2RY14 423/4885ALOX5 131/4885PTGER4 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.